Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Phase 3positiveAglatimagene BesadenovecPositive
AI Analysis
Summary
Candel Therapeutics announced publication of pivotal Phase 3 data in The Lancet Oncology demonstrating that aglatimagene besadenovec (CAN-2409) achieved significant improvement in disease-free survival in patients with localized prostate cancer.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Significant improvement in disease-free survival demonstrated in pivotal Phase 3 data
Importance:8/10
Sentiment:
0.85
Phase 3 dataprostate cancerdisease-free survivalpivotal trialpublication
Related Companies
Read the original article
Published by yahoo_finance on June 2, 2026 12:05 PM